<DOC>
	<DOCNO>NCT02505776</DOCNO>
	<brief_summary>This post-marketing surveillance study Japan evaluate safety patient satisfaction GLASH VISTA™ ( bimatoprost cutaneous solution 0.03 % ) treatment hypotrichosis eyelash .</brief_summary>
	<brief_title>Safety Patient Satisfaction With GLASH VISTA™ ( Bimatoprost 0.03 % ) Treatment Eyelash Hypotrichosis Japan</brief_title>
	<detailed_description />
	<mesh_term>Hypotrichosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Patients prescribed GLASH VISTA™ clinical setting fill least one prescription GLASH VISTA™ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>